Compare Abeona Therapeutics Inc (ABEO) vs Duke Energy Corp (DUK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Duke Energy Corp — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while Duke Energy Corp trades at $127.16 (market cap $99.96B). The key difference: Duke Energy Corp is far larger — about 267.8× Abeona Therapeutics Inc's market cap, and Duke Energy Corp pays a 3.32% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | DUK | |
|---|---|---|
Market Cap | $373.32M | $99.96B |
Sector | Health | Utilities |
52-Week High | $7.23 | $133.46 |
52-Week Low | $4.17 | $113.99 |
Enterprise Value | $228.22M | $190.00B |
Dividend Yield | — | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Duke Energy (DUK) trades at $128.22, down 1.06% on the day, with a bullish technical signal supported by moving averages. The company shows steady revenue growth, reaching $32.24B in 2025, and has beaten earnings estimates for the last three quarters. A $1.07 dividend is scheduled for June 2026. Analyst consensus is a Buy with a $137.67 price target, though the stock faces headwinds from high debt levels and regulatory pressures.
DUK presents a stable investment with consistent earnings and a solid dividend, but investors should weigh the upside from infrastructure investments against rising debt and regulatory risks. The stock's current valuation is reasonable, with potential for moderate growth if execution on its $103B capital plan remains on track.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →
